Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-08-15
2006-08-15
Mosher, Mary E. (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388150, C530S387300, C530S389400
Reexamination Certificate
active
07091324
ABSTRACT:
Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4415491 (1983-11-01), Vyas
patent: 4683136 (1987-07-01), Milich et al.
patent: 5106726 (1992-04-01), Wang
patent: 5308750 (1994-05-01), Mehta et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5514539 (1996-05-01), Bukh et al.
patent: 5574132 (1996-11-01), Lacroix
patent: 5670153 (1997-09-01), Weiner et al.
patent: 5695390 (1997-12-01), Mizuno et al.
patent: 5709995 (1998-01-01), Chisari et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5843639 (1998-12-01), Reyes et al.
patent: 5871962 (1999-02-01), Bukh et al.
patent: 5985609 (1999-11-01), Min et al.
patent: 6020122 (2000-02-01), Okasinski et al.
patent: 6020167 (2000-02-01), Thoma
patent: 6027729 (2000-02-01), Houghton et al.
patent: 6074846 (2000-06-01), Ralston et al.
patent: 6110706 (2000-08-01), Thoma
patent: 6121020 (2000-09-01), Selby et al.
patent: 6538114 (2003-03-01), Persson et al.
patent: WO 97/40176 (1997-10-01), None
patent: WO 99/24054 (1998-11-01), None
patent: WO 00/26418 (2000-05-01), None
Burioni et al., Dissection of Human Humoral Immune Response Against Hepatitis C Virus E2 Glycoprotein by Repertoire Cloning and Generation of Recombinant Fab Fragments. Hepatology 28(3):810-814, 1998.
Mondelli et al., Significance of the Immune Response to a Major, Conformational B-Cell Epitope on the Hepatitis C Virus NS3 Region Defined by a Human Monoclonal Antibody. Journal of Virology 68(8): 4829-4836, 1994.
Deleersnyder et al., Formation of Native Hepatitis C Virus Glycoprotein Complexes. Journal of Virology 71(1):697-704, 1997.
Da Silva Cardoso et al., Isolation and Characterization of Human Monoclonal Antibodies Against Hepatitis C Virus Envelope Glycoproteins. Journal of Medical Virology 55:28-34, 1998.
Habersetzer et al., Isolation of human monoclonal antibodies (HMabs) directed at conformational determinants of the heptitis C virus (HCV) E2 envelope protein. Hepatology 24(4), Pt. 2, 381A, Abstract 1020, 1996.
Abrignani, S., “Immune Responses Throughout Hepatitis C Virus (HCV) Infection: HCV from the Immune System Point of View”,Springer Semin Immunopathol, 19: 47-55, 1997.
Akatsuka, et al., “B-Cell Epitopes on the Hepatitis C Virus Nucleocapsid Protein Determined by Human Monospecific Antibodies”,Hepatology, 18: 503-510, 1993.
Burioni, et al., “Dissection of Human Humoral Immune Response Against Hepatitis C Virus E2 Glycoprotein by Repertorie Cloning and Generation of Recombinant Fab Fragments”,Hepatology, 28: 810-814, 1998.
Burton and Barbas, et al., “Human Antibodies from Combinatorial Libraries”,Advances in Immunology, 57:191-280.
da Silva Cardosa, et al., “Isolation and Characterization of Human Monoclonal Antibodies Against Hepatitis C Virus Envelope Glycoproteins”,J. Med. Virology, 55: 28-34, 1998.
DeLalla, et al., “Properties of a Human Monoclonal Antibody Specific for the NS4 Region of Hepatitis C Virus”,J. Hepatol.18:163-167, 1993.
Deleersnyder et al., “Formation of Native Hepatitis C Virus Glycoprotein Complexes”,J. Virology, 71:697-704, 1997.
Foung, et al., “Rescue of Human Monoclonal Antibody Production from an EBV-Transformed B Cell Line by Fusion to a Human-Mouse Hybridoma”,J. Immunol. Methods, 701:83-90, 1990.
Habersetzer, et al., “Characterization of Human Monoclonal Antibodies Specific to the Hepatitis C Virus Glycoprotein E2 with In Vitro Binding Neutralization Properties”,Virology, 249: 32-41, 1998.
Hadlock, et al., “Neutralizing Human Monoclonal Antibodies to Conformational Epitopes of Human T-Cell Lymphotropic Virus Type 1 and 2 gp46”,J. Virology, 71:5828-5840, 1997.
Landford, et al., “Analysis of Hepatitis C Virus Capsid, E1, and E2/NS1 Proteins Expressed in Insect Cells”,Virology, 197: 225-235, 1993.
Mahaney, et al., “Genotypic Analysis of Hepatitis C Virus in American Patients”,Hepatology, 20: 1405-1411, 1994.
Meola, et al., Derivation of Vaccines from Mimotopes, Immunologic Properties of Human Hepatitis B Virus Surface Antigen Mimotopes Displayed on Filamentous Phage,J. Immunol.154:3162-3172, 1995.
Mondelli, et al., “Significance of the Immune Response to a Major, Conformational B-Cell Epitope on the Hepatitis C Virus NS3 Region Defined by a Human Monoclonal Antibody”,J. Virol.68:4829-4836, 1994.
Moradpour, et al., “Characterization of Three Novel Monoclonal Antibodies Against Hepatitis C Virus Core Protein”,J. Med. Virol.48:234-241, 1996.
Plaisant et al., “Human Monoclonal Recombinant Fabs Specific for HCV Antigens Obtained by Repertoire Cloning in Phage Display Combinatorial Vectors”,Res. Virol.148:-169, 1997.
Puntoriero, et al., “Towards a Solution for Hepatitis C Virus Hypervariability: Mimotopes of the Hypervariable Region 1 Can Induce Antibodies Cross-Reacting with a Large Number of Viral Variants”,EMBO J. 17:3521-3533, 1998.
Ralston, et al., “Characterization of Hepatitis C Virus Envelope Glycoprotein Complexes Expressed by Recombinant Vaccinia Viruses”,J. Virology, 67:6753-6761, 1993.
Rosa, et al., “A Quantitative Test to Estimate Neutralizing Antibodies to the Hepatitis C Virus: Cytofluorimetric Assessment of Envelope Glycoprotein 2 Binding to Target Cells”,PNAS USA, 93:1759-1763, 1996.
Siemoneit, et al., “Isolation and Eptiope Characterization of Human Monoclonal Antibodies to Hepatitis C Virus Core Antigen”,Hybridoma, 13:9-13, 1994.
Siemoneit, et al., “Human Monoclonal Antibodies for the Immunological Characterization of a Highly Conserved Protein Domain of the Hepatitis C Virus Glycoprotein E1”Clin. and Experimental Immun. 101:278-283, 1995.
Simmonds, “Variability of Hepatitis C Virus”,Hepatology, 21:570-583, 1995.
Tafi, et al, “Identification of HCV Core Mimotopes: Improved Methods for the Selection and Use of Disease-Related Phage-Displayed Peptides”,Biol. Chem. 378:495-502, 1997.
Ward, et al., “Stringent Chemical and Thermal Regulation of Recombinant Gene Expression by Vaccinia Virus Vectors in Mammalian Cells”,Proc. N.H. Acad. Sci., USA, 92: 6773-6777, 1995.
Zimmerman, et al., “Efficient Hybridization of Mouse-Human Cell Lines by Means of Hypo-Osmolar Electrofusion”,J. Immunol. Methods. 134: 43-50, 1990.
International Search Report issued for corresponding PCT application PCT/US01/45029, 2003.
Chan, S-W, et al., “Human recombinant antibodies specific for hepatitis C virus core and envelope E2 peptides from an immune phage display library”,Journal of General Virology, 77:251-2539, 1996.
Database EMBL Online retrieved from EBI Database accession No. Q81497, XP002222487 abstract, 1996.
Hadlock, K.G. et al, Human Monoclonal Antibodies That Inhibit Binding Of Hepatitis C Virus E2 Protein to CD81 and Recognize Conserved Conformational Epitopes,J. Virology, 74:10407-10416, 2000.
Prince, A. et al., Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins,Journal of Viral Hepatitis, 3:11-17, 1996.
Foung Steven K. H.
Hadlock Kenneth G.
Keck Zhen-yong
Baker C. Hunter
Board of Trustees of Leland Stanford Junior University
Choate Hall & Stewart LLP
Jarrell Brenda Hershbach
Mosher Mary E.
LandOfFree
Prevention and treatment of HCV infection employing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of HCV infection employing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of HCV infection employing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3698746